The largest published, multi-center clinical trial for any currently available prescription weight management medication in the U.S., with more than 1,000 participants, is detailed in the March edition of the journal Obesity Research. This clinical trial represents the first of a whole new era of comprehensive evaluation for obesity pharmacotherapy at multiple doses. Also, the health benefits tied to improvements in cholesterol levels add significance to these findings.
Obesity is a growing public health problem in America.
Some 55 percent of all U.S. adults are overweight or obese, affecting more than 97 million Americans. All patients had regular medical check-ups which included measurement of body weight, blood pressure and pulse rate. The study demonstrates a statistically significant dose-related response in terms of percent change in weight for patients compared to placebo. In this study, the most common treatment-related adverse events were dry mouth, anorexia and insomnia. The adverse events discontinuation rate was eight percent for placebo and 11 percent for all study participants.